Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin

US10092571B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Klaus Dugi · Dresden, DE
• Eva Ulrike GRAEFE-MODY · Ingelheim am Rhein, DE
• Michael Mark · Biberach an der Riß, DE
• Hans-Juergen WOERLE · Munich, DE
• Heike ZIMDAHL-GELLING · Biberach an der Riß, DE

Key dates

• Filing date: Aug 12, 2016
• Grant date: Oct 9, 2018
• Expiry date: Aug 12, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P3/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.